markdown
📉 The Financial Deep Dive
The Numbers:
Viyash Scientific Limited (formerly Sequent Scientific Limited) presented a complex financial picture for Q3 FY26. On a consolidated basis, revenue from operations climbed 10.9% YoY to ₹8,584.10 crore. Profit After Tax (PAT) demonstrated robust growth, surging 33.6% YoY to ₹273.70 crore. However, consolidated basic Earnings Per Share (EPS) saw a decline of 14.4% YoY to ₹0.89 from ₹1.04 in Q3 FY25, primarily due to an increased share count post-amalgamation.
For the nine months ended December 31, 2025 (9M FY26), consolidated revenue rose 11.9% YoY to ₹25,003.50 crore. Consolidated PAT witnessed an exceptional surge of 371.4% YoY to ₹2,679.90 crore, with EPS increasing to ₹2.91 from ₹1.15. These significant jumps in 9M consolidated figures are attributed to the Composite Scheme of Amalgamation becoming effective and the subsequent restatement of prior period financials using the 'Pooling of Interest' method.
Conversely, standalone performance painted a different story. Q3 FY26 revenue grew marginally by 1.6% YoY to ₹3,416.40 crore. Standalone PAT, however, declined by 19.6% YoY to ₹400.60 crore from ₹498.40 crore. Consequently, standalone basic EPS fell 31.6% YoY to ₹0.93 from ₹1.36. For 9M FY26, standalone revenue increased 4.5% YoY to ₹10,095.70 crore, and PAT grew 37.2% YoY to ₹674.70 crore. Standalone EPS still declined YoY to ₹0.93 from ₹1.36.
The Quality:
The consolidated results for Q3 FY26 included substantial exceptional expenses of ₹412.60 crore, primarily related to costs associated with the Composite Scheme of Amalgamation. This significantly impacted the reported PAT. The company also noted the application of hyperinflationary accounting for its Turkish subsidiaries, adding a layer of complexity to its international operations. The divergence between strong consolidated PAT growth and declining standalone PAT/EPS, coupled with a drop in consolidated EPS despite PAT growth, suggests a nuanced interpretation is required. The restatement of prior periods due to amalgamation means direct historical comparisons for operational trends can be challenging.
The Grill:
The provided filing does not contain transcripts of a management call or details of analyst interrogations. Therefore, specific analyst questions or management responses regarding a 'grill' are not available for analysis.
🚩 Risks & Outlook
The key risk for investors lies in interpreting the amalgamated financial statements. The significant impact of the Composite Scheme of Amalgamation, including restated prior periods and substantial exceptional costs, makes direct YoY comparisons difficult. Investors must discern the underlying operational performance from the adjusted consolidated figures and the standalone results. The decline in standalone PAT and EPS, alongside the consolidated EPS dip, warrants close monitoring. The integration success of the amalgamation and the resolution of exceptional costs will be critical. The application of hyperinflationary accounting for Turkish operations adds further uncertainty. Investors should watch for clearer guidance on future operational profitability, the true impact of the amalgamation on market share and synergies, and how the company navigates its distinct standalone and consolidated performance trends.
Viyash Scientific Q3: Consolidated PAT Surges, Standalone Earnings Dip Amid Amalgamation
HEALTHCAREBIOTECH
Overview
Viyash Scientific reported mixed Q3 FY26 results. Consolidated PAT jumped 33.6% YoY to ₹273.70 crore, driven by strong revenue growth. However, standalone PAT fell 19.6% to ₹400.60 crore, and consolidated EPS declined YoY due to increased share count post-amalgamation. Significant exceptional costs of ₹412.60 crore were incurred for the Composite Scheme of Amalgamation, which also led to prior period restatements.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.